Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with Cobimetinib or Idasanutlin in ER+ Metastatic Breast Cancer
NCT03566485Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab, cobimetinib and idasanutlin in breast cancer (2 arms), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Started Jul 2018; status: terminated.
02
Drugs
atezolizumabcobimetinibidasanutlin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03566485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03566485.